Numerous investigations into gastrointestinal tumors have revealed that IRF-1 exhibits a ‘double-edged sword’ role, simultaneously promoting and inhibiting tumor progression by regulating various downstream factors mediated by the IFN-γ/STAT1 pathway. Here, STAT1 is linked to neoplasm.